Clincosm LogoSign in Get a demo

Expressive Writing for COVID-19 Resilience

Sponsor
Duke University (Other)
Overall Status
Completed
CT.gov ID
NCT04589104
Collaborator
(none)
63
Enrollment
1
Location
1
Arm
2.7
Actual Duration (Months)
23.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the impact of a 6-week, virtually-delivered expressive writing intervention on resilience in a cohort of individuals currently navigating the COVID-19 pandemic during spring 2020.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Expressive writing
 N/A

Detailed Description

The purpose of this study is to determine the impact of a 6-week, virtually-delivered expressive writing intervention on resilience in a cohort of individuals currently navigating the COVID-19 pandemic during spring 2020.

Eligible subjects will be adults who are able to read and write in English and are cognitively able to provide informed consent. Potential subjects will be recruited through the Duke Health & Well-Being email lists. The entirely virtual 6-week expressive writing intervention will be delivered via Zoom, REDCap, and email, and subjects will complete measures at baseline, 6 weeks, and 10 weeks (1 month post-intervention). Each week of the intervention will invite participants to complete a series of expressive writing assignments designed to support emotional expression and cultivate resilience, and the assignments will take approximately 60-90 minutes each week to complete.

The primary outcome is the 25-item Connor-Davidson Resilience Scale (CD-RISC). Other measures will include a basic demographics survey, questions about COVID-19 impact, post-writing surveys collected after the writing assignments, the 10-item Perceived Stress Scale (PSS), the Center for Epidemiologic Studies Depression Scale-Revised, and the 21-item Post -Traumatic Growth Inventory (PTGI). Participants will also have the option to share the content of their writing assignments with the research team if they choose.

The risks of participation in this study are minimal and include the risk of mild sadness after the writing assignments and the risk of loss of confidentiality.

Study Design

Study Type:
Interventional
Actual Enrollment :
63 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Expressive Writing for COVID-19 Resilience
Actual Study Start Date :
May 26, 2020
Actual Primary Completion Date :
Aug 17, 2020
Actual Study Completion Date :
Aug 17, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Expressive writing

The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows: Week 1: Writing to expressive difficult emotions Week 2: Writing to release & integrate difficult emotions Week 3: Writing to nurture gratitude Week 4: Writing to enhance strengths & resources Week 5: Writing to cultivate positive meaning & savor goodness Week 6: Writing to invite insight, perspective, & growth

Behavioral: Expressive writing
The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows: Week 1: Writing to expressive difficult emotions Week 2: Writing to release & integrate difficult emotions Week 3: Writing to nurture gratitude Week 4: Writing to enhance strengths & resources Week 5: Writing to cultivate positive meaning & savor goodness Week 6: Writing to invite insight, perspective, & growth

Outcome Measures

Primary Outcome Measures

  1. Resilience [3 months]

    Connor-Davidson Resilience Scale (CD-RISC)

Secondary Outcome Measures

  1. Perceived stress [3 months]

    Perceived Stress Scale-10 (PSS10)

  2. Depression symptoms [3 months]

    Center for Epidemiologic Studies Scale - Revised (CESDR)

  3. Post-traumatic growth [3 months]

    Post Traumatic Growth Inventory (PTGI)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

Potential subjects will be considered eligible if they feel they have been personally impacted by circumstances surrounding COVID-19. Other eligibility criteria include:

  • Able to speak, read, write, and understand English

  • Cognitively able to provide consent

  • Ability to participate in a 6-week intervention delivered via Zoom, REDCap, and email

Contacts and Locations

Locations

Site City State Country Postal Code
1 Duke Integrative Medicine Durham North Carolina United States 27705

Sponsors and Collaborators

  • Duke University

Investigators

  • Principal Investigator: Oliver Glass, PhD, Duke University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Duke University
ClinicalTrials.gov Identifier:
NCT04589104
Other Study ID Numbers:
  • Pro00105575
First Posted:
Oct 19, 2020
Last Update Posted:
Oct 19, 2020
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
COVID-19

Study Results

No Results Posted as of Oct 19, 2020